UB Paderborn / Katalog / Suche / in CDI

Wong‐Type Dermatomyositis in an African American Patient

Arthritis & rheumatology (Hoboken, N.J.), 2021-04, Vol.73 (4), p.630-630

2021

Volltextzugriff (PDF)

Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis

Journal of the American Academy of Dermatology, 2018-04, Vol.78 (4), p.769-775.e2

2018

Volltextzugriff (PDF)

Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia Mimicking Discoid Lupus Erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2019-03, Vol.71 (3), p.478-478

2019

Volltextzugriff (PDF)

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM

Arthritis research & therapy, 2022-03, Vol.24 (1), p.69-69, Article 69

2022

Volltextzugriff (PDF)

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM

Arthritis research & therapy, 2022-01, Vol.24 (1), p.1-12, Article 12

2022

Volltextzugriff (PDF)

Managing interventional clinical trials in the setting of COVID-19: Experience in an autoimmune skin disease unit

JAAD international, 2021-03, Vol.2, p.94-95

2021

Volltextzugriff (PDF)

The effects of immunostimulatory herbal supplements on autoimmune skin diseases

Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1051-1058

2021

Volltextzugriff (PDF)

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial

Journal of investigative dermatology, 2022-10, Vol.142 (10), p.2651-2659.e1

2022

Volltextzugriff (PDF)

Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus

Journal of the American Academy of Dermatology, 2021-06, Vol.84 (6), p.1562-1567

2021

Volltextzugriff (PDF)

Treatment of Autoimmune Bullous Disorders in Pregnancy

American journal of clinical dermatology, 2018-06, Vol.19 (3), p.391-403

2018

Volltextzugriff (PDF)

Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations

Journal of investigative dermatology, 2019-02, Vol.139 (2), p.270-276

2019

Volltextzugriff (PDF)

The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review

Annals of translational medicine, 2021-03, Vol.9 (5), p.431-431

2021

Volltextzugriff (PDF)

Elephantiasic Pretibial Myxedema: A Rare Manifestation in Graves’ Disease

Journal of Health Science and Medical Research (JHSMR), 2019-05, Vol.37 (2), p.151-155

2019

Volltextzugriff (PDF)

The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria

British journal of dermatology (1951), 2019-05, Vol.180 (5), p.1001-1008

2019

Volltextzugriff (PDF)

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin: Disease A Randomized Clinical Trial

Journal of investigative dermatology, 2022-04, Vol.142 (10), p.2651-2659.e1

2022

Volltextzugriff (PDF)

Correction to: Cannabinoid type 2 receptor and in vivo efects of LenabasumTM

Arthritis research & therapy, 2022-03, Vol.24 (1)

2022

Volltextzugriff (PDF)

Cannabinoid type 2 receptor and in vivo effects of LenabasumTM

Arthritis research & therapy, 2022-01, Vol.24 (1)

2022

Volltextzugriff (PDF)

AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus

Annals of translational medicine, 2021-03, Vol.9 (5), p.AB005-AB005

2021

Volltextzugriff (PDF)

AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus

Annals of translational medicine, 2021-03, Vol.9 (5), p.AB004-AB004

2021

Volltextzugriff (PDF)

AB014. Developing classification criteria for skin-predominant dermatomyositis: assessing the methodology of the prospective validation study

Annals of translational medicine, 2021-03, Vol.9 (5), p.AB014-AB014

2021

Volltextzugriff (PDF)

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of Lenabasum TM

Arthritis research & therapy, 2022-03, Vol.24 (1), p.69

2022

Volltextzugriff (PDF)

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum TM

Arthritis research & therapy, 2022-01, Vol.24 (1), p.12

2022

Volltextzugriff (PDF)

Clinical Images: Lichen planus pigmentosus and frontal fibrosing alopecia mimicking discoid lupus erythematosus

Arthritis & rheumatology (Hoboken, N.J.), 2018-11

2018

Volltextzugriff (PDF)

Chapter 28 - Skin

Lahita's Systemic Lupus Erythematosus, 2021, p.447-469

Sixth Edition, 2021

Volltextzugriff (PDF)

Alopecias in lupus erythematosus

Lupus science & medicine, 2018-01, Vol.5 (1), p.e000291-e000291

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Wong‐Type Dermatomyositis in an African American Patient

Re-examining mechanic's hands as a characteristic skin finding in dermatomyositis

Lichen Planus Pigmentosus and Frontal Fibrosing Alopecia Mimicking Discoid Lupus Erythematosus

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of LenabasumTM

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of LenabasumTM

Managing interventional clinical trials in the setting of COVID-19: Experience in an autoimmune skin disease unit

The effects of immunostimulatory herbal supplements on autoimmune skin diseases

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial

Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus

Treatment of Autoimmune Bullous Disorders in Pregnancy

Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus—An Ongoing Need for International Consensus and Collaborations

The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review

Elephantiasic Pretibial Myxedema: A Rare Manifestation in Graves’ Disease

The diagnosis and classification of amyopathic dermatomyositis: a historical review and assessment of existing criteria

Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin: Disease A Randomized Clinical Trial

Correction to: Cannabinoid type 2 receptor and in vivo efects of LenabasumTM

Cannabinoid type 2 receptor and in vivo effects of LenabasumTM

AB005. Assessing meaningful changes in disease activity as clinical trial clinical efficacy measures for cutaneous lupus erythematosus

AB004. Evaluating differences in meaningful change in disease activity between different races and clinical subtypes affected by cutaneous lupus erythematosus

AB014. Developing classification criteria for skin-predominant dermatomyositis: assessing the methodology of the prospective validation study

Correction to: Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo efects of Lenabasum TM

Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCs) and in vivo effects of Lenabasum TM

Clinical Images: Lichen planus pigmentosus and frontal fibrosing alopecia mimicking discoid lupus erythematosus

Chapter 28 - Skin

Alopecias in lupus erythematosus

Suchergebnisse filtern